Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Swedish Orphan Biovitrum AB Sobi
Swedish Orphan Biovitrum AB Sobi
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Ingredients
Therapeutic: efanesoctocog alfa for haemophilia A
Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Recruitment
Sobi appoints Head of Technical Operations
Research & Development
Sobi Orfadin capsules approved in Saudi Arabia
Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Estates & Facilities
Sobi opens office in Greece
The company is welcomed by those hoping for innovative therapeutic solutions in Greece
Regulatory
Sobi’s Elocta approved in Switzerland for the treatment of haemophilia A
Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages
Manufacturing
Sobi signs manufacturing agreements with Pfizer
Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Chief Medical Officer Birgitte Volck to leave Sobi
To join GlaxoSmithKline as Head of R&D Rare Diseases
Subscribe now